Bacterial vaginosis (BV) is a common condition affecting 10–30% of women in developed nations. The current recommended treatment for BV is oral or vaginal antibiotics; however, recurrence rates of up to 60% within 12 months of treatment have been reported previously. The present study aimed to evaluate the efficacy of Bacillus coagulans (SNZ-1969) against BV and the ability of this bacterial species to prevent BV recurrence in women aged 18–41 years. The study assessed 173 women, and of these women, 120 showed recurrent BV according to Nugent’s and Amsel’s criteria. These 120 women were randomly assigned to the following study arms: metronidazole arm and metronidazole + B. coagulans arm. The metronidazole + B. coagulans arm showed better success (86.6%) in treating and minimizing recurrence of vaginal infections and consequently symptoms associated with BV, owing to the large number of lactobacilli administered in the B. coagulans arm. Oral supplementation with probiotics can be an efficient approach for the treatment of BV. Oral therapy for a longer duration would be more effective despite intestinal passage, vaginal ascension, and growth of lactobacilli requiring a long time. Long-term administration could probably allow controlled release of lactobacilli for preventing recurrence of BV.